DIGITAL BIOMARKERS

Digital biomarkers are changing the face of clinical trials. By allowing for the collection of high-density data, we can gain new, more powerful insights into the ability of novel agents to modulate or modify disease. Biospective has performed multiple digital biomarker studies for its sponsors, from single site, exploratory/early phase studies to large-scale, multi-center and home-based studies. We provide end-to-end solutions for digital biomarker studies, and we have implemented processes for the acquisition, quality control, and analysis of this “Big Data”.

MULTI-CENTER & HOME-BASED STUDIES

GRETEL™ is Biospective’s cross-platform, modular, web-based software solution for data and project management in multi-center and home-based studies. The power of GRETEL™ stems from its ability to combine clinical, neuropsychiatric, imaging, and digital biomarker data from all subjects into a single, user-friendly, fully-transparent system.
DIGITAL BIOMARKER CAPABILITIES

EARLY & EXPLORATORY PHASE STUDIES

CITE™ (Centers for Investigational, Translational, and Exploratory studies) is Biospective’s network of world-class research centers and collaborators used to facilitate exploratory & early phase studies. The capabilities of these facilities include:

- Functional Assessment
  - Gait/Posture/Balance
  - Range of Motion & Strength
- Metabolic Activity & Body Composition
- Functional Assessment
- Imaging
  - MRI (GE, Philips, Siemens)
  - PET/CT
  - SPECT/CT

VALIDATION STUDIES

Before deployment of novel technologies in later phase studies, it is vital to validate these tools against accepted gold-standards, as well as determine the sensitivity of these putative biomarkers to disease state and progression. Through our CITE™ platform, we work closely with technology and pharmaceutical companies to efficiently and cost-effectively test new technologies in healthy subjects and patient populations.

ProtoKinetics Zeno Walkway

NeuroCom Equitest

CONTACT BIOSPECTIVE

info@biospective.com
1-514-360-0141